Company intelligence / Profile preview

Blip

Los Angeles, California, United States

Ownership: Private
Development stage: Other

Overview

Blip commercializes FDA-approved nicotine gum and lozenge therapies, with evidence that nicotine replacement roughly doubles quit success rates. It uniquely combines NRT with digital and community support, and has a partnership with Truth Initiative’s EX Program (clinical digital behavioral support), expanding access and reach among young adults.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Truth Initiative (EX Program behavioral support partnership)

Beyond the preview

Go deeper on Blip.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blip.

Explore the full profile